Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT02853565 is registered in ClinicalTrials.gov with CANbridge Life Sciences Ltd. as lead sponsor.

NCT NCT02853565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02853565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Lead sponsor
CANbridge Life Sciences Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2016
Completion date
September 30, 2018
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme